Rybelsus

ApprovedSmall molecule

Pfizer

Rybelsus is one of 131 small molecule programs targeting Alcoholic Fatty Liver Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

130

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alcoholic Fatty Liver DiseaseActive, not recruiting

Pancreatic CancerActive, not recruiting

Type 2 DiabetesActive, not recruiting

ObesityActive, not recruiting

Alcoholic Fatty Liver DiseaseApproved

Active, not recruiting

Pancreatic CancerPreclinical

Active, not recruiting

Type 2 DiabetesPhase 2

Active, not recruiting

ObesityPhase 1

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Rybelsus

Pfizer

Approved

1 2

Gemzar

GGynecologic Oncology Group

Medrol

1 4

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 5

Active Comparator

Moderna

Preclinical

1 6

LDE225

Novartis

Preclinical

1 7

Sulfonylureas

Eli Lilly

Preclinical

1 8

Thiazolidinediones

Sanofi

Preclinical

1 9

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

1 10

Chemotherapy Agents

Takeda

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Not yet recruiting

Type 2 Diabetes

NCT07487103

Q3 2027

Phase 1Recruiting

Obesity

NCT06446531

Clinical

Trials by Indication[1]

Type 2 Diabetes2 trials

Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity

Terminated· Pfizer logo

Pfizer·Phase 2·NCT05579977·902 enrolled

Efficacy and Safety of QLG1090 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT07487103·478 enrolled

Pancreatic Cancer1 trial

Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data

Unknown status· Novo Nordisk logo

Novo Nordisk··NCT04572165·600,000 enrolled

Obesity1 trial

Prevention of Progression of Prediabetes, Obesity and CV Risk

Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT06446531·64 enrolled

Alcoholic Fatty Liver Disease1 trial

Semaglutide in Nonalcoholic Fatty Liver Disease

Completed·ZZagazig University·Phase 4·NCT05813249·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Rybelsus. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rybelsus compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rybelsus. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Pfizer

Rybelsus

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Trials by Indication[1]

Type 2 Diabetes2 trials

Pancreatic Cancer1 trial

Obesity1 trial

Alcoholic Fatty Liver Disease1 trial

References

Drug Info

Quick Facts

Related News